About Seraxis
Seraxis Leadership Team
William L. Rust, Ph.D. Chief Executive Officer, Founder, Director of Board
William Rust devoted his career to developing stem cells as therapies and research tools at ES Cell International, Lonza and the ATCC. Will launched Seraxis based on his concept for a more potent cell therapy for diabetes. For this work he was granted multiple families of patents in the US and worldwide for the technologies behind the Seraxis stem cell, the Seraxis pancreas organoid, and the technology to improve allo-compatibility. By providing successful strategic direction to the company, he was able to grow Seraxis from start-up through several rounds of financing to position Seraxis as an industry leader in organoid replacement therapy for type 1 diabetes. Will earned his Ph.D. from UNLV and completed a research fellowship in the transplant department of Novartis.
Carole A. Welsch, Ph.D., MBA, Chief Operating Officer, Co-Founder
Carole Welsch is an experienced pharmaceutical and biotech executive with positions of increasing responsibilities at Novartis, Vanda Pharmaceuticals, and QIAGEN. She brings extensive expertise from her prior roles leading marketing, medical and business development teams in Oncology, CNS disorders and Metabolic Diseases. Carole oversees the Company’s operations. She holds a Ph.D. in Molecular Biology from University Louis Pasteur, Strasbourg and an M.B.A. from Nanyang Business School (NBS), Singapore. She completed a fellowship at the National Cancer Center of Singapore (NCCS).
Board of Directors
Jerry Baty, JD, CPA
Jerry is a Partner with Newport LLC providing CEO advisory services to middle market companies to help them prepare financially and organizationally for the changes associated with either buy-side or sell-side M&A, product expansion, market expansion or other transformational events. Before entering the advisory industry, Jerry was the CEO of SafeTech USA, Inc., a company in the aviation safety equipment service industry, which he sold in a PE backed strategic deal. Prior to SafeTech, Jerry held the position of CFO for several development stage biotech, pharma and medical device companies, leading their efforts in fundraising, business development, planning and reporting and execution of exit strategies. In addition to Seraxis, Jerry currently serves as a board member for Lighthouse for Students and is a member of the Audit Committee for the Houston Symphony. Jerry holds a J.D. from South Texas College of Law, an M.B.A. from the University of Houston, C.T. Bauer College of Business, and a B.B.A. in accounting from Stephen F. Austin State University. He is a licensed CPA in Texas and is licensed to practice law in New York.
William Rust, Ph.D.
Dr. Rust is both an active member of the Board of Directors and a shareholder in the company. He has successfully raised several rounds of private equity funding to support Seraxis growing operations. Dr. Rust works with other members of the Board to design a long-term corporate strategy that delivers maximum value to shareholders while keeping on target the SERAXIS mission of curing type 1 diabetes.
Partnerships
Seraxis is interested in pursuing strategic partnerships with organizations interested in bringing novel therapies to patients. Seraxis invites proposals of scientific collaborations and licensing opportunities around its technologies, across geographies and indications.
Careers
We are a rapidly growing regenerative medicine company focused primarily on a replacement cell therapy for insulin-dependent diabetes. Dedicated professionals who are excited to join the team that overcomes all challenges in a rewarding environment are invited to apply.
Publications & Presentations
Stay up-to-date with the latest thought leadership on regenerative medicine technologies, including pancreatic islet replacement therapy.
